Table 3 Univariate and multivariate analyses of survival in patients undergoing radical cystectomy and pelvic lymphadenopathy
Progression-free survival | Cancer-specific survival | Overall survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
Lymph node status | ||||||||||||
Group 1; PVLN(−)/non-PVLN(−) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||||
Group 2; PVLN(+)/non-PVLN(−) | 2.086 (0.325–13.38) | 0.438 | 0.559 (0.117–2.665) | 0.465 | 33.28 (1.719–644.3) | 0.020 | 3.570 (0.525–24.27) | 0.193 | 3.224 (0.593–17.54) | 0.176 | 1.977 (0.496–7.874) | 0.334 |
Group 3; PVLN(−)/non-PVLN(+) | 6.191 (1.869–20.51) | 0.003 | 1.523 (0.570–4.068) | 0.401 | 8.894 (1.128–70.34) | 0.038 | 3.166 (0.630–15.93) | 0.162 | 1.403 (0.423–4.657) | 0.580 | 1.657 (0.509–5.398) | 0.402 |
Group 4; PVLN(+)/non-PVLN(+) | 22.62 (6.259–81.76) | < 0.001 | 1.448 (0.571–3.671) | 0.435 | 142.6 (25.61–794.0) | < 0.001 | 7.667 (1.894–31.05) | 0.004 | 12.36 (3.751–40.72) | < 0.001 | 3.474 (1.376–8.771) | 0.008 |
Age (years) | ||||||||||||
≤ 69 | 1 (reference) | NA | 1 (reference) | NA | 1 (reference) | NA | ||||||
≥ 70 | 1.237 (0.662–2.313) | 0.505 | 1.074 (0.431–2.675) | 0.878 | 1.581 (0.847–2.951) | 0.150 | ||||||
Sex | ||||||||||||
Male | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||||
Female | 0.601 (0.279–1.297) | 0.195 | 1.066 (0.379–2.996) | 0.904 | 0.289 (0.091–0.917) | 0.035 | < 0.001 (0-Infinity) | 0.997 | 0.543 (0.248–1.191) | 0.128 | 0.503 (0.170–1.486) | 0.214 |
Neoadjuvant chemotherapy | ||||||||||||
No | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||||
Yes | 2.994 (1.117–8.028) | 0.029 | 2.484 (1.036–5.952) | 0.041 | 0.865 (0.214–3.504) | 0.840 | 0.615 (0.121–3.134) | 0.559 | 0.636 (0.243–1.664) | 0.356 | 0.507 (0.150–1.710) | 0.274 |
Histology | ||||||||||||
Conventional | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||||
Variants | 0.951 (0.441–2.050) | 0.898 | 0.475 (0.183–1.234) | 0.126 | 1.525 (0.490–4.746) | 0.466 | 1.723 (0.488–6.083) | 0.398 | 2.039 (0.947–4.386) | 0.069 | 1.442 (0.614–3.391) | 0.401 |
pT stage | ||||||||||||
≤ 2 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||||
≥ 3 | 5.547 (2.917–10.55) | < 0.001 | 5.829 (2.238–15.18) | < 0.001 | 6.293 (2.494–15.88) | < 0.001 | 2.716 (0.623–11.87) | 0.184 | 3.392 (1.796–6.406) | < 0.001 | 2.057 (0.842–5.024) | 0.113 |
Surgical margin | ||||||||||||
Negative | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||||
Positive | 7.764 (2.086–28.89) | 0.002 | 1.766 (0.681–4.578) | 0.242 | 4.713 (0.752–29.53) | 0.098 | 2.640 (0.588–11.86) | 0.205 | 4.051 (1.148–14.30) | 0.030 | 2.472 (0.949–6.443) | 0.064 |
Adjuvant therapy | ||||||||||||
No | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||||
Yes | 5.929 (2.700–13.02) | < 0.001 | 1.867 (0.891–3.914) | 0.098 | 5.372 (1.835–15.73) | 0.002 | 1.205 (0.429–3.387) | 0.724 | 1.365 (0.644–2.896) | 0.417 | 0.619 (0.289–1.324) | 0.216 |